[Journal of Hepatocellular Carcinoma] This research examines the medical challenges presented by pediatric hepatocellular carcinoma (HCC).
Profile of Tivantinib and its Potential in the Treatment of Hepatocellular Carcinoma: The Evidence to DateDecember 08, 2016
[Journal of Hepatocellular Carcinoma] This research examines tivantinib and its therapeutic profile in the management of hepatocellular carcinoma.
Prognostic role of pretreatment serum albumin in renal cell carcinoma: a systematic review and meta-analysisNovember 24, 2016
[OncoTargets and Therapy] This research examines the prognostic value of pretreatment serum albumin in RCC patients.
[Journal of Hepatocellular Carcinoma] This research examines the screening modalities, diagnosis, staging, and treatment of hepatocellular carcinoma (HCC), the most common primary liver malignancy.
Role of Regorafenib as Second-line Therapy and Landscape of Investigational Treatment Options in Advanced Hepatocellular CarcinomaOctober 27, 2016
[Journal of Hepatocellular Carcinoma] This review examines the multikinase inhibitors sorafenib and regorafenib, inhibitors of the MET pathway, and immunotherapeutics for the treatment of advanced hepatocellular carcinoma.
In patients with advanced HCC and a baseline αFP level of 400 ng/mL or more, a survival benefit with second-line ramucirumab therapy was observed for those with Child-Pugh scores of 5 and 6.
The multikinase inhibitor regorafenib significantly improved overall survival rates compared to placebo in patients with hepatocellular carcinoma, according to data from the phase 3 RESORCE trial.
Comparative Efficacy and Safety of Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-analysisJuly 07, 2016
[Oncotargets and Therapy] This research evaluates the comparative efficacy and safety of axitinib and sorafenib for the treatment of metastatic renal cell carcinoma.
Including an antiemetic in the preprocedure medications for patients with liver cancer undergoing drug eluting bead chemoembolization (DEB TACE) can shorten hospital stays and reduce the chance for readmission due to complications.
In patients with advanced hepatocellular carcinoma (HCC), adding doxorubicin to sorafenib did not improve overall survival or progression-free survival and resulted in higher toxicity compared to sorafenib alone, results from a phase 3 study presented at the ASCO 2016 Annual Meeting have shown.
A study of nearly 1000 patients with HCC found that black patients with the disease had a 33% greater risk of death compared with non-Hispanic whites.
Oncology nurses are in an ideal position to educate patients with gastrointestinal malignancies and PVT about risk factors, clinical presentation, complications, and treatment options to prevent further extension of the clot.
An interdisciplinary collaboration between prominent academic and industry investigators discovered a novel method for repositioning an FDA-approved anticancer compound so it can specifically target liver cancer tumors.
RNA test of blood platelets can detect, classify, and pinpoint the location of cancer by analyzing a sample equivalent to 1 drop of blood. Using this new method, researchers were able to identify cancer with 96% accuracy.
Patients undergoing oncologic liver surgeries who participated in an enhanced recovery program returned sooner to their normal life function and to adjuvant cancer therapies than patients who were treated with a traditional approach to perioperative care.
Results of a meta-analysis shows reduction in rate of infection and shorter length of hospital stay with receipt of prebiotics and probiotics before surgery.
Women with intrahepatic cholestasis of pregnancy (ICP) are at increased risk of hepatobiliary cancer.
The risk of hepatobiliary cancer and immune-mediated and cardiovascular diseases later in life is increased in women with intrahepatic cholestasis of pregnancy (ICP) than in women without this condition.
Long-term therapy with tenofovir was associated with a decreased incidence of HCC among patients with chronic HBV infection without cirrhosis.
Livers donated to cancer patients by individuals that died of cardiac death do not yield outcomes worse than those donated by people dying from brain death.
Significant clinical variations have been identified among patients with hepatocellular carcinoma (HCC).
Patients with liver cancer have the same positive outcomes using organs donated by patients who died as a result of cardiac death.
A surgical approach in which less than one lobe of the liver is removed in a patient undergoing resection for liver cancer is linked to lowered mortality and complication rates, according to new study results.
The amount of alcohol a person has to drink to risk developing liver cancer has been narrowed down.
The risk of disease recurrence in liver cancer patients who have undergone a liver transplant can now be more accurately calculated, thanks to new tool.
An interventional x-ray guidance device approved by the U.S. Food and Drug Administration in 2013 may have the potential to reduce the radiation exposure of patients undergoing intra-arterial therapy for liver cancer.
AlluraClarity, an FDA-approved X-ray guidance device, has the potential to reduce radiation exposure in patients with liver cancer.
Triclosan, a popular antimicrobial agent in soaps, detergents, and plastics, has been found to promote liver cancer in mice.
Liver tumor cells do not respond to sorafenib if they have a less differentiated phenotype, known as the mesenchymal type, and express CD44, according to a new study.
Patients that have inoperable advanced hepatocellular carcinoma (HCC) may live significantly longer by receiving a combined therapy, according to recent trial results.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|